arrow
C

Christian Hampp

regeneron pharmaceuticals inc
H指数:21
被引数:1,577

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Second Primary Malignancy in Patients with DLBCL Receiving CAR T Therapy and Other Systemic Anticancer Therapy: Real-World Evidence from a Large US National Claims Database

弥漫大B细胞淋巴瘤患者接受CAR T疗法及其他系统性抗肿瘤治疗后的第二原发恶性肿瘤:来自大型美国国家理赔数据库的真实世界证据

2026-10-220
PRE
Infection risk and management in patients with relapsed/refractory multiple myeloma treated with linvoseltamab in the LINKER-MM1 study

在LINKER-MM1研究中,接受林诺塞特单抗治疗的复发/难治性多发性骨髓瘤患者的感染风险与管理

2026-10-010
OAAI
Effectiveness of linvoseltamab versus real-world standard-of-care in triple-class-exposed relapsed/refractory multiple myeloma in the United States

在美国三药类暴露的复发/难治性多发性骨髓瘤中,林洛塞坦单抗相较于真实世界标准疗法的有效性

2026-04-010
OAAI
Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma

林伏塞尔塔马布与真实世界国际骨髓瘤工作组三药类暴露的复发/难治性多发性骨髓瘤标准护理的比较

2026-03-250
OAAI
Comparative effectiveness of odronextamab monotherapy versus real-world systemic therapies in R/R follicular lymphoma

奥德诺克单抗单药治疗与真实世界全身性疗法在复发/难治性滤泡性淋巴瘤中的比较疗效

2026-02-010
PRE
Prognostic factors and effect modifiers in patients with relapsed or refractory follicular lymphoma who failed at least two lines of therapy: a systematic literature and expert clinical review

预后因素和效应修饰因子在至少接受过两线治疗失败后复发或难治性滤泡性淋巴瘤患者中的研究:一项系统文献和专家临床综述

2025-09-020
OAAI
Teratogenic Risk Impact Mitigation (TRIM): Development of Explicit Criteria to Facilitate Decisions Regarding Teratogenic Risk Mitigation Strategies

致畸风险影响缓解(TRIM):明确标准的发展,以促进关于致畸风险缓解策略的决策

2025-08-050
OAAI
Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review

对复发/难治性多发性骨髓瘤预后因素重要性的排序:基于系统文献综述的国际医师专家组共识

2025-04-030
OAAI